

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

**ESMO
PRECEPTORSHIP**

**ZURICH SWITZERLAND
16-17 DECEMBER 2022**

From the essentials of tumour
immunology to clinical application.

Co-Chairs

James Larkin, United Kingdom
Inge Marie Svane, Denmark

ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

Zurich, Switzerland
16-17 December 2022

CO-CHAIRS James Larkin, United Kingdom
Inge Marie Svane, Denmark

SPEAKERS Fabrice André, France
Andrés Cervantes, Spain
Nicoletta Colombo, Italy
Alessandra Curioni-Fontecedro, Switzerland
Marco Donia, Denmark
Angela Lamarca, Spain
Paul Nathan, United Kingdom
Solange Peters, Switzerland
Santiago Zelenay, United Kingdom

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 16 December 2022

09:00-09:10 10'	Welcome and Introduction	Inge Marie Svane, DK
09:10-10:25 75'	SESSION 1 Essentials of tumour immunology	Chair: Inge Marie Svane, DK
30'	Basic tumour immunology for oncologists	Marco Donia, DK
30'	Mechanisms of immune resistance	Santiago Zelenay, UK
15'	Discussion	Faculty
10:25-10:55	Coffee break	
10:55-12:30 95'	SESSION 2 Essentials in immunotherapy	Chair: James Larkin, UK
20'	The historical view on cancer immunotherapy	Inge Marie Svane, DK
30'	Developments in Immune Checkpoint Inhibition	James Larkin, UK
30'	Developments in adoptive T-Cell transfer	Inge Marie Svane, DK
15'	Discussion	Faculty
12:30-13:30	Lunch	
13:30-14:30 60'	SESSION 3 Clinical development – part I	Chair: James Larkin, UK
25'	Immunotherapy for breast cancer	Fabrice André, FR
25'	Immunotherapy for renal cell cancer	Paul Nathan, UK
10'	Discussion	Faculty
14:30-15:30 60'	SESSION 4 Clinical development – part II	Chair: Inge Marie Svane, DK
25'	Immunotherapy for melanoma	James Larkin, UK
25'	Immunotherapy for gastro-intestinal cancers	Andrés Cervantes, ES
10'	Discussion	Faculty
15:30-16:00	Coffee break	
16:00-17:00 60'	SESSION 5 Clinical development – part III	Chair: James Larkin, UK
25'	Immunotherapy for NSCLC	Solange Peters, CH
25'	Immunotherapy for SCLC and mesothelioma	Alessandra Curioni-Fontecedro, CH
10'	Discussion	Faculty
17:00-17:40 40'	SESSION 6 Audience cases	Chair: Inge Marie Svane, DK
40'	Participants' clinical case discussion (4x10')	Faculty
19:00	Dinner	

Saturday, 17 December 2022

08:30-09:10 40'	SESSION 7 Audience cases	Chair: James Larkin, UK
40'	Participants' clinical case discussion (4x10')	Faculty
09:10-10:10 60'	SESSION 8 Clinical development – part IV	Chair: Inge Marie Svane, DK
25'	Immunotherapy for liver and biliary cancer	Angela Lamarca, ES
25'	Immunotherapy for gynaecological malignancies	Nicoletta Colombo, IT
10'	Discussion	Faculty
10:10-10:40	Coffee break	
10:40-11:40 60'	SESSION 9 Immunomonitoring and microbiota	Chair: James Larkin, UK
25'	Biomarkers for immunotherapy	Inge Marie Svane, DK
25'	Microbiota and immunotherapy	Paul Nathan, UK
10'	Discussion	Faculty
11:40-12:40 60'	SESSION 10 Immune toxicity and management	Chair: Inge Marie Svane, DK
45'	IrAEs and management of toxicities	James Larkin, UK
15'	Discussion	Faculty
12:40-12:50 10'	General discussion	James Larkin, UK Inge Marie Svane, DK
12:50-14:00	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion